Breaking News Instant updates and real-time market news.

VRX

Valeant

$10.07

0.23 (2.34%)

, MRK

Merck

$63.97

0.59 (0.93%)

13:38
05/07/17
05/07
13:38
05/07/17
13:38

Valeant announces new hires in dermatology, corporate communications

Valeant Pharmaceuticals (VRX) announced Friday appointments to the dermatology leadership team of Michael McMyne, who has joined as vice president of Sales, and Stacey Williams, who has joined as vice president of Marketing. Additionally, the company announced Lainie Keller has joined as vice president of Corporate Communications. McMyne most recently served as vice president of operations for Merz North America, a specialty pharmaceutical and medical device company focused on dermatology, aesthetics medicine and neurosciences. Prior to this new role, Williams was senior marketing director for Merz North America. "We are committed to securing the company's future in the dermatology space, and I look forward to working with these talented leaders to realize the full potential of this key business for Valean," remarked Bill Humphries, executive vice president and company group chairman, Valeant Dermatology. Meanwhile, in a newly created role, Keller will be responsible for executing external corporate communications and media relations strategies for Valeant. She joined the company from Merck (MRK), where she most recently served as a director of corporate media relations.

VRX

Valeant

$10.07

0.23 (2.34%)

MRK

Merck

$63.97

0.59 (0.93%)

  • 07

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 23

    May

  • 27

    May

  • 31

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

  • 24

    Aug

VRX Valeant
$10.07

0.23 (2.34%)

03/18/17
WELS
03/18/17
NO CHANGE
WELS
Underperform
Valeant management positive on new FDA guidelines, says Wells Fargo
Wells Fargo analyst David Maris said in a research note late Friday that Valeant Pharmaceuticals views the FDA's new guidance for generic Xifaxan as a positive. Management believes the guidelines may delay generics which may not have conducted their studies to be compliant with the new guidance, Maris told investors in a research note. The analyst earlier in the day Friday told investors that he views the FDA's guidance as a "game changing development that makes it much easier for generics to show bioequivalence." Maris called the news a "new significant negative" for Valeant. He says his initial read is not changed by Valeant management's view, but added that he will review the feedback with outside consultants and other industry sources to gain a broader perspective. Maris has an Underperform rating on Valeant, his firm's equivalent of a sell. Shares of Valeant closed yesterday down 17c to $11.03.
04/05/17
WELS
04/05/17
NO CHANGE
WELS
Underperform
Valeant may break $10 amid lukewarm iNova interest, Wells Fargo says
According to the Australian Business Review, Valeant Pharmaceuticals' iNova unit has received lukewarm interest with bids coming in under $1B, Wells Fargo analyst David Maris tells investors in a research note. This is another disappointment as some investors had expected $1B in proceeds for the unit, the analyst adds. What was promised to be $8B worth of asset sales has thus far only been approximately $2B, Maris points out. He is not surprised by today's report, however, noting Valeant's recent debt refinancing was a sign that "near term asset sales of significant value are not at hand." Maris adds that he wouldn't be surprised if Valeant shares break the "psychological price point of $10" in the near-term since management is yet to demonstrate a turnaround. The analyst keeps an Underperform rating on the shares. The drugmaker in early trading is down 4c to $10.13.
04/11/17
PIPR
04/11/17
NO CHANGE
Target $10
PIPR
Underweight
Piper dermatologist survey shows Siliq won't change Valeant's fortunes
After surveying 27 medical dermatologists, Piper Jaffray analyst David Amsellem does not believe Siliq can change the fortunes of Valeant Pharmaceuticals' dermatology segment. Siliq is likely to lag "far behind" other IL-17A antagonists in terms of adoption for treatments of moderate-to-severe plaque psoriasis, Amsellem tells investors in a research note. The analyst thinks Valeant's "sanguine commentary about the product is overly optimistic." He reiterates an Underweight rating on the shares with a $10 price target. Valeant closed yesterday up 26c to $9.85.
04/21/17
WELS
04/21/17
NO CHANGE
WELS
Wells Fargo's Maris cuts Valeant price target range to $7-$9
Wells Fargo analyst David Maris cut his price target range for Valeant Pharmaceuticals to $7-$9 from $10-$13 and keeps an Underperform rating on the name. The drug maker closed yesterday down 14c to $8.88. Valeant shares are not worth the risk, Maris tells investors in a research note. He believes the company will not generate enough free cash flow between now and 2023 to pay its debt maturities. While Valeant's earnings may exceed near-term consensus estimates, investors have better opportunities elsewhere, Maris contends.
MRK Merck
$63.97

0.59 (0.93%)

04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.
04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.
05/03/17
BMOC
05/03/17
NO CHANGE
BMOC
Merck results more positive than first appeared, says BMO Capital
BMO Capital analyst Alex Arfaei says he's more upbeat on Merck's Q1 results following its conference call. He says that the lower than expected Januvia revenue is "explainable," while the company's Keytruda drug looks set to beat expectations in 2H17. The analyst expects the company's 2017 results to come in at the top half of its guidance range, and he thinks the stock can rise, driven by Keytruda and its hepatitis C treatments. The analyst keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

CBS

CBS

$51.75

0.14 (0.27%)

21:20
05/20/18
05/20
21:20
05/20/18
21:20
Upgrade
CBS rating change at Bernstein »

CBS upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNX

Knight-Swift

$40.63

0.89 (2.24%)

20:40
05/20/18
05/20
20:40
05/20/18
20:40
Upgrade
Knight-Swift rating change at Stifel »

Knight-Swift upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

, FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

19:24
05/20/18
05/20
19:24
05/20/18
19:24
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

CBS

CBS

$51.75

0.14 (0.27%)

ROKU

Roku

$35.40

1.14 (3.33%)

LOW

Lowe's

$86.31

0.85 (0.99%)

GE

General Electric

$14.98

-0.05 (-0.33%)

WAB

Wabtec

$95.23

1.1 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 22

    May

  • 23

    May

  • 12

    Jun

JHG

Janus Henderson Group

$32.43

-0.3 (-0.92%)

18:38
05/20/18
05/20
18:38
05/20/18
18:38
Hot Stocks
Janus Henderson Group announces dividend of 36c »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHG

Philips

$43.01

0.26 (0.61%)

17:29
05/20/18
05/20
17:29
05/20/18
17:29
Hot Stocks
New data shows combined COPD treatments could help reduce annual cost of care »

At the American Thoracic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$94.26

1.37 (1.47%)

, CMCSA

Comcast

$32.72

0.3 (0.93%)

16:45
05/20/18
05/20
16:45
05/20/18
16:45
Hot Stocks
Box Office Battle: 'Deadpool 2' debuts at number 1 with $125M »

Ryan Reynolds and…

TWX

Time Warner

$94.26

1.37 (1.47%)

CMCSA

Comcast

$32.72

0.3 (0.93%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$48.60

-0.2 (-0.41%)

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

LGF.A

Lionsgate

$24.27

0.3 (1.25%)

DIS

Disney

$103.94

-0.4 (-0.38%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

TSLA

Tesla

$276.84

-7.6 (-2.67%)

16:28
05/20/18
05/20
16:28
05/20/18
16:28
Periodicals
ISS recommending Tesla shareholders split chairman, CEO role, Bloomberg says »

The largest proxy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, SPX

S&P 500

$0.00

(0.00%)

16:23
05/20/18
05/20
16:23
05/20/18
16:23
Periodicals
China agrees to import more from U.S., no sign of $200B target, Reuters says »

China has agreed to…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$14.98

-0.05 (-0.33%)

, WAB

Wabtec

$95.23

1.1 (1.17%)

16:19
05/20/18
05/20
16:19
05/20/18
16:19
Periodicals
GE nearing deal to merge transportation unit with Wabtec, Reuters says »

General Electric (GE) is…

GE

General Electric

$14.98

-0.05 (-0.33%)

WAB

Wabtec

$95.23

1.1 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 12

    Jun

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, SPX

S&P 500

$0.00

(0.00%)

16:17
05/20/18
05/20
16:17
05/20/18
16:17
Periodicals
Trump administration walks back Chinese tariff plans, Axios says »

Treasury Secretary Steve…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$77.47

0.965 (1.26%)

16:13
05/20/18
05/20
16:13
05/20/18
16:13
Hot Stocks
Dillard's announces 10c cash dividend »

Dillard's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCYT

Veracyte

$6.45

-0.07 (-1.07%)

16:11
05/20/18
05/20
16:11
05/20/18
16:11
Hot Stocks
Data shows 'real-world' value of Afirma GSC in thyroid cancer diagnosis »

Veracyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 12

    Jun

MCHP

Microchip

$92.80

-0.1865 (-0.20%)

, MSCC

Microsemi

$68.60

(0.00%)

15:42
05/20/18
05/20
15:42
05/20/18
15:42
Conference/Events
Microsemi to host special shareholder meeting »

Special shareholder…

MCHP

Microchip

$92.80

-0.1865 (-0.20%)

MSCC

Microsemi

$68.60

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HDNG

Hardinge

$18.44

0.03 (0.16%)

15:35
05/20/18
05/20
15:35
05/20/18
15:35
Conference/Events
Hardinge to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRG

Bravo Brio Restaurant

$4.05

(0.00%)

15:30
05/20/18
05/20
15:30
05/20/18
15:30
Conference/Events
Bravo Brio Restaurant to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/20/18
05/20
04:55
05/20/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

CBS

CBS

$51.75

0.14 (0.27%)

, VIA

Viacom

$33.80

-0.75 (-2.17%)

13:23
05/19/18
05/19
13:23
05/19/18
13:23
Periodicals
CBS looks like a bargain, Barron's says »

In a follow-up story,…

CBS

CBS

$51.75

0.14 (0.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

, PEP

PepsiCo

$97.51

-0.45 (-0.46%)

13:10
05/19/18
05/19
13:10
05/19/18
13:10
Periodicals
Coca-Cola, PepsiCo look like bargains, Barron's says »

Investors have punished…

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$35.40

1.14 (3.33%)

10:32
05/19/18
05/19
10:32
05/19/18
10:32
Periodicals
Roku relevance worth taking note of, Barron's says »

Roku now is mostly a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

LOW

Lowe's

$86.31

0.85 (0.99%)

10:19
05/19/18
05/19
10:19
05/19/18
10:19
Periodicals
Lowe's turnaround what matters for long-term investors, Barron's says »

With Lowe's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AAPL

Apple

$186.31

-0.69 (-0.37%)

, ZTCOY

ZTE Corp.

$0.00

(0.00%)

08:41
05/19/18
05/19
08:41
05/19/18
08:41
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$186.31

-0.69 (-0.37%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

ACIA

Acacia Communications

$32.97

0.45 (1.38%)

OCLR

Oclaro

$8.88

-0.015 (-0.17%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

GM

General Motors

$37.80

-0.51 (-1.33%)

F

Ford

$11.33

-0.12 (-1.05%)

FCAU

Fiat Chrysler

$21.86

-0.31 (-1.40%)

HMC

Honda

$32.98

-0.11 (-0.33%)

TM

Toyota

$136.04

-0.54 (-0.40%)

NSANY

Nissan

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VRX

Valeant

$22.15

0.12 (0.54%)

PFE

Pfizer

$35.64

-0.07 (-0.20%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

INSY

Insys Therapeutics

$6.95

-0.37 (-5.05%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

BAYRY

Bayer

$0.00

(0.00%)

GILD

Gilead

$68.01

0.41 (0.61%)

BMRN

BioMarin

$88.95

0.51 (0.58%)

MNK

Mallinckrodt

$15.70

-0.37 (-2.30%)

SHPG

Shire

$169.62

-2.18 (-1.27%)

MRK

Merck

$59.13

0.06 (0.10%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

TEVA

Teva

$21.23

0.12 (0.57%)

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

ACOR

Acorda Therapeutics

$23.65

-0.45 (-1.87%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

NVS

Novartis

$77.08

-0.07 (-0.09%)

RHHBY

Roche

$0.00

(0.00%)

GALE

Galena

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 24

    May

  • 25

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 22

    Aug

  • 27

    Aug

  • 07

    Sep

  • 10

    Sep

  • 12

    Sep

  • 05

    Oct

  • 23

    Oct

  • 13

    Nov

  • 20

    Dec

  • 21

    Dec

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/19/18
05/19
04:55
05/19/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

18:46
05/18/18
05/18
18:46
05/18/18
18:46
Hot Stocks
Solid Biosciences announces new preclinical data for SGT-001 »

Solid Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

18:04
05/18/18
05/18
18:04
05/18/18
18:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.4K…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

FXE

Euro Currency Trust

$113.01

-0.28 (-0.25%)

FXC

CurrencyShares Canadian Dollar Trust

$76.61

-0.38 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$114.04

0.11 (0.10%)

18:02
05/18/18
05/18
18:02
05/18/18
18:02
Hot Stocks
Celanese raises prices for emulsion polymers and acetyls »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.